Oxford Biomedica shares surge after it raises its forecast for COVID-19 vaccine revenues
A look at the major movers on the London market on Tuesday
Oxford Biomedica PLC (LON:OXB) has been boosted by vaccine news.
The company, a key manufacturer of the Oxford/AstraZeneca PLC (LON:AZN) COVID-19 vaccine, has doubled its expectations for revenue from the contract.
The gene and cell therapy group said AstraZeneca had increased the number of batches required for the jab in the second half.
It now estimates its revenues from the vaccine will be £100mln, up from previous forecasts of £50mln.
The company's shares have jumped 128p or 12.77% to 1130p, making it the biggest riser in the FTSE 350.